Skip to main content
Figure 2 | Molecular Pain

Figure 2

From: Small organic molecule disruptors of Cav3.2 - USP5 interactions reverse inflammatory and neuropathic pain

Figure 2

Cav3.2/USP5 ELISA screening results. (A) Competition affinity ELISA assay. A non-biotinylated human Cav3.21569–1589-III-IV peptide (21 mer) was used to compete off the interaction between the biotinylated Cav3.2 Cav3.21556–1602-III-IV peptide (46 mer) and hUSP5. (B) Screening of a 5000 bioactive compound library using a 384 well capacity ELISA. A group of active compounds (~50% inhibition) were identified. (C) Structure and concentration response curve for suramin in the ELISA assay. (D) Structure and concentration response curve for gossypetin in the ELISA assay.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us